Drug Profile

Pertuzumab biosimilar - Xuanzhu Biopharmaceutical

Alternative Names: XZP-KM118

Latest Information Update: 31 Mar 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Xuanzhu Biopharmaceutical
Developer Beijing ShuangLu Pharmaceutical; Xuanzhu Biopharmaceutical
Class Antineoplastics; Immunotherapies; Monoclonal antibodies
Mechanism of Action Antibody-dependent cell cytotoxicity; Dimerisation inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

03 Mar 2023 Phase-II clinical trials in HER2 Positive Breast cancer in China, prior to March 2023 (Xuanzhu Biopharm pipeline, March 2023)
03 Mar 2023 Phase-II clinical trials in Solid tumours in China, prior to March 2023 (Xuanzhu Biopharm pipeline, March 2023)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com